

INPRESS TECHNOLOGIES

INPRESS  TECHNOLOGIES

Innovation

Postpartum hemorrhage (PPH), defined as excess bleeding after childbirth, is the leading cause of maternal death worldwide and takes the life of one woman every four minutes. Eighty percent of PPH cases are caused by uterine atony, the failure of the uterus to contract to its original size, leaving blood vessels fully dilated and bleeding unobstructed.

The InPress is a single-use medical device that specifically addresses uterine atony. Rather than merely treating the symptoms of postpartum hemorrhage, the InPress stops bleeding by stimulating the body's natural response: uterine contraction. After childbirth, the InPress is inserted into the uterus, where its proprietary mechanism works to gently contract the uterus back to the correct postpartum size. Without pharmaceuticals or surgery, the InPress stops blood flow immediately by addressing the driving cause of hemorrhage.

The InPress dramatically reduces cost and risk to the patient. As uterine atony affects women all over

the world, there is a clear and immediate need for the device. In the United States, European Union, and select other countries, we hope the InPress device becomes the standard of care, providing an alternative to a regimen of pharmaceuticals and invasive surgeries, like hysterectomy. In emerging markets, this device will provide an affordable treatment to PPH, and save the lives of the millions of women. The total addressable market for acute postpartum hemorrhage is \$1.9 billion.



For more information, contact: Jessie Becker, 916-947-0881 or jrbecker10@gmail.com.

Innovation is the lifeblood of medical advancement and the key to raising the bar for patient care. Yet the traditional process for medical innovation is fraught with obstacles that hinder the development of new ideas. That's why Dr. Thomas Fogarty, a preeminent physician innovator, founded this educational, nonprofit organization. Here, we build upon Dr. Fogarty's invaluable experience to provide a streamlined alternative path for entrepreneurial innovators working on promising new therapies. We hand select several candidates for inclusion in our Innovation Cultivation program, and provide access to expert intellectual, physical, and financial resources designed to propel medical concepts from initiation to application. The program offers direct mentorship every step of the way. InPress is one of the showcase participants in the program.



**Fogarty Institute
for Innovation**

For more information, contact Ann Fyfe, President & CEO, at 650-988-7590 or ann.fyfe@fogartyinstitute.org.